Investigating the function of the OSM-OSMR axis in pancreatic ductal adenocarcinoma (PDAC)

被引：0
|
作者：
Sui, Yuan
Hunter, Tony
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6984
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinicopathologic Characteristics and Biologic Behavior of Concurrent Pancreatic Ductal Adenocarcinoma (PDAC)
    Lew, M.
    Morales-Oyarvide, V.
    Liao, X.
    Ogino, S.
    Chen, J-H
    Pitman, M. B.
    Mino-Kenudson, M.
    LABORATORY INVESTIGATION, 2012, 92 : 446A - 446A
  • [42] Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
    Mosalem, Osama M.
    Abdelhakeem, Ahmed
    Abdel-Razeq, Nayef H.
    Babiker, Hani
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025, 34 (03) : 149 - 160
  • [43] Genomic characterization of ATM alterations in advanced pancreatic ductal adenocarcinoma (PDAC).
    Perera, Sheron
    Denroche, Robert Edward
    Holter, Spring
    Kelly, Deirdre
    Zhang, Amy
    Wang Yifan
    Dodd, Anna
    Ramotar, Stephanie
    Hutchinson, Shawn
    Tehfe, Mustapha
    Ramjeesingh, Ravi
    Biagi, James Joseph
    Wilson, Julie
    Notta, Faiyaz
    Fischer, Sandra
    Zogopoulos, George
    Grant, Robert C.
    Gallinger, Steven
    Knox, Jennifer J.
    O'Kane, Grainne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [44] Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
    Chen, Hao
    Luo, Wenhao
    Lu, Xiaoyue
    Zhang, Taiping
    HELIYON, 2023, 9 (11)
  • [45] Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).
    George, Ben
    Bailey, Mark
    Schrock, Alexa Betzig
    Thorpe, Lauren
    Gay, Laurie M.
    Ritch, Paul S.
    Thomas, James P.
    Erickson, Beth
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Stephens, Philip J.
    Miller, Vincent A.
    Ross, Jeffrey S.
    Singhi, Aatur D.
    Ali, Siraj Mahamed
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Mechanisms of microRNA-21 dysregulation in pancreatic ductal adenocarcinoma (PDAC).
    Zimmerman, Jacquelyn W.
    Burkhart, Richard A.
    Fertig, Elana J.
    Jaffee, Elizabeth M.
    CANCER RESEARCH, 2021, 81 (13)
  • [47] Dual targeting of mTOR and ErbB pathways in pancreatic ductal adenocarcinoma (PDAC)
    Broussard, Brett L.
    Arnoletti, Juan P.
    Mikhaylina, Alevtina
    Heslin, Martin J.
    Frolov, Andrey
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (03) : S136 - S136
  • [48] Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview
    Panchal, Kanan
    Sahoo, Rakesh Kumar
    Gupta, Umesh
    Chaurasiya, Akash
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
  • [49] THE SIGNIFICANCE OF SURGICAL "MARGINS" IN WHIPPLE SPECIMENS FOR PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
    Kang, Liang-I
    Liu, Jingxia
    Carpenter, Danielle
    Williams, Greg
    Chatterjee, Deyali
    GASTROENTEROLOGY, 2018, 154 (06) : S522 - S522
  • [50] The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
    Brown, Matthew
    Zhang, Wanbin
    Yan, Deyue
    Kenath, Rajath
    Le, Le
    Wang, He
    Delitto, Daniel
    Ostrov, David
    Robertson, Keith
    Liu, Chen
    Pham, Kien
    PLOS ONE, 2020, 15 (01):
12345